Acquisition by Reed Tuckson of 80000 shares of CTi Biopharma subject to Rule 16b-3

CTICDelisted Stock  USD 9.09  0.00  0.00%   
About 56% of CTi Biopharma's investor base is looking to short. The analysis of current outlook of investing in CTi Biopharma Corp suggests that many traders are alarmed regarding CTi Biopharma's prospects. The current market sentiment, together with CTi Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use CTi Biopharma Corp stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Cti Biopharma Corp director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
CTi insider trading alert for grant of stock option right to buy by Reed Tuckson, the corporate stakeholder, on 7th of April 2023. This event was filed by Cti Biopharma Corp with SEC on 2023-04-07. Statement of changes in beneficial ownership - SEC Form 4

CTi Biopharma Fundamental Analysis

We analyze CTi Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

CTi Biopharma is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

CTi Biopharma Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CTi Biopharma stock to make a market-neutral strategy. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with similar companies.

Peers

CTi Biopharma Related Equities

FBIOFortress Biotech   9.52   
0%
100.0%
CRVSCorvus Pharmaceuticals   7.45   
0%
78.0%
CDTXCidara Therapeutics   4.82   
0%
50.0%
VSTMVerastem   3.58   
0%
37.0%
ELEVElevation Oncology   3.28   
0%
34.0%
XFORX4 Pharmaceuticals   2.94   
0%
30.0%
VKTXViking Therapeutics   2.75   
0%
28.0%
RIGLRigel Pharmaceuticals   2.34   
0%
24.0%
IBRXImmunitybio   1.59   
0%
16.0%
TGTXTG Therapeutics   1.01   
10.0%
0%
MCRBSeres Therapeutics   1.12   
11.0%
0%
PLXProtalix Biotherapeutics   1.75   
18.0%
0%
MDGLMadrigal Pharmaceuticals   2.45   
25.0%
0%
RVPHReviva Pharmaceuticals   2.61   
27.0%
0%
PDSBPDS Biotechnology   2.76   
28.0%
0%
IMMPImmutep   5.45   
57.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format